DRG Epidemiology’s coverage of Stargardt disease (STGD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence in each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s STGD forecast will answer the following questions:
How will demographic trends, such as population aging, improving life expectancy, and population migration, affect the epidemiology of STGD over the ten-year forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following subpopulations:
Diagnosed incident cases.
Diagnosed prevalent cases.
Diagnosed incident cases by visual acuity in the worst eye.
Diagnosed prevalent cases by visual acuity in the worst eye.
Diagnosed Prevalence of Stargardt Disease per 100,000 People of All Ages in 2018 and 2028
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Stargardt Disease over the Next Ten Years
Number of Additional Prevalent Cases of Stargardt Disease in 2028 in the Countries Under Study due to Trends in Riskttttttt
Epidemiology Data
Methods
Diagnosed Incident Cases of Stargardt Disease
Diagnosed Prevalent Cases of Stargardt Disease
Stargardt Disease by Visual Acuity
Reference Materials
Literature Review
Studies Included in the Analysis
Studies Excluded from the Analysis
Risk/Protective Factors
Bibliography
Narendra Parihar
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
